NYSE:ELN

E559465

NYSE:ELN was the stock ticker symbol for Elan Pharmaceuticals, an Irish biotechnology company known for developing treatments for neurological and autoimmune diseases.

All labels observed (1)

Label Occurrences
NYSE:ELN canonical 2

How this entity was disambiguated

Statements (47)

Predicate Object
instanceOf biotechnology company
public company
acquiredBy Perrigo Company plc
linked to: Perrigo
acquisitionDate 2013
acquisitionValue approximately $8.6 billion
collaboratedWith Biogen Idec
linked to: Biogen

Johnson & Johnson
Wyeth
countryOfOrigin Ireland
currencyOfStock GBP
linked to: Pound sterling

USD
delistedFrom LSE
NYSE
developedFor Alzheimer's disease
Crohn's disease
multiple sclerosis
focusesOn autoimmune diseases
neurological diseases
formerTicker LSE:ELA
NYSE:ELN
foundedBy Don Panoz
foundedIn 1969
headquartersLocation Dublin, Ireland
linked to: Dublin
industry biotechnology
pharmaceuticals
ISIN IE0003072950
legalIssue accounting and financial reporting investigations in early 2000s
listedOn LSE
NYSE
notableEvent Tysabri safety concerns and temporary market withdrawal in 2005
reintroduction of Tysabri with risk management program
notableMarket Europe
United States
notableProduct Antegren
Bapineuzumab
linked to: bapineuzumab

Tysabri
primaryTherapeuticArea immunology
neurology
reasonForDelisting acquisition by Perrigo
researchFocus biologic therapies
central nervous system disorders
monoclonal antibodies
status defunct as independent company
stockExchange London Stock Exchange
New York Stock Exchange
tradedAs LSE:ELA
NYSE:ELN

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Elan Pharmaceuticals tradedAs NYSE:ELN
Elan Corporation plc formerTicker NYSE:ELN
subject linked to: NYSE:ELN